Report Scope & Overview:
The Anti-Fungal Treatment Market Size was valued at USD 15.21 billion in 2022, and is expected to reach USD 20.03 billion by 2030 and grow at a CAGR of 3.5% over the forecast period 2023-2030.
Antifungal treatment, sometimes referred to as antimycotic treatment, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycoses such cryptococcal meningitis, candidiasis, ringworm, and others. To treat fungal infections, many antifungal medications are available. Antifungal drugs come in many distinct varieties. They may also be administered intravenously, topically, or orally. The rise in nosocomial and fungal diseases is the key factor driving the market for antifungal treatment. However, it is anticipated that a spike in initiatives by individuals and private organisations to raise awareness about the wide range of fungal illnesses will expand the global markets for antifungal treatments.
To Get More Information on Anti-Fungal Treatment Market - Request Sample Report
Awareness of the Many Fungal Infections is Growing
More and more over-the-counter antifungal medications (OTC)
Antifungal Drug Use for a Wide Range of Medical Conditions is Growing in Developing Regions
Issues with Medicine
Drug Resistance to Antifungals is Growing
Antifungal Drug Adverse Reactions
R&D activities are becoming more prevalent.
Antifungal medications have a high price tag.
Resistance to antifungal drugs is spreading throughout the people
Underdeveloped countries' inadequate healthcare infrastructure
IMPACT OF COVID-19
Over the projected period, it is expected that the COVID-19 outbreak would constrain the market for antifungal medications. the COVID-19 virus has spread to almost every nation on earth, prompting the World Health Organization (WHO) to declare it a public health emergency. A new coronavirus called COVID-19 was identified as the cause of the pneumonia cases. Rapid global spread of this virus resulted in a large number of fatalities. the WHO proclaimed COVID-19 a global pandemic and recommended stringent measures to stop the disease's spread. Since then, the pandemic has delayed the growth of the healthcare sector and disrupted the supply chain.
Flight restrictions had an effect on the market for antifungal drugs in the first quarter. Strict social distancing laws and supply chain disruptions have had an impact on the antifungal drug industry. However, the market for antifungal medications, which had been languishing, has been revived as a result of economies unblocking during the second quarter. Government officials in the majority of countries have also imposed nationwide lockdowns in an effort to halt the spread of COVID-19. Similar issues were plaguing health systems around the world that made it difficult to keep up supply chains. The demand for antifungal drugs has also been hampered by the supply chain's slowness.
By Drug Class
The market was led by the azoles segment, and this trend is anticipated to persist over the projected period due to an increase in the occurrence of invasive fungal infections and the prevalence of diabetes. As a result, the market is growing due to the increase in antifungal medicine usage.
By Infection Type
Due to an increase in aspergillosis instances and a rise in the manufacturing of oral or intravenous medications like voriconazole, which can treat the invasive kind of aspergillosis, the systematic antifungal infection segment has been driving market expansion. But because there are more cases of candidiasis, a yeast-caused fungal infection, that segment of the market for superficial antifungal infections is anticipated to develop significantly throughout the projected period.
By Therapeutic Indications
The candidiasis segment is driving market expansion. Candidiasis is a fungal infection brought on by yeasts and is classified as belonging to the genus Candida as a result of the increase in candida organism proliferation. But due to an increase in aspergillus molds, the aspergillosis segment is anticipated to have significant growth during the projection period.
By Drug Class
By Infection Type
Superficial Antifungal Infections
Systemic Antifungal Infections
By Therapeutic Indications
By Dosage Forms
Need any customization research on Anti-Fungal Treatment Market - Enquiry Now
Due to the rising rate of mucormycotic cases, the presence of major players, the growth of the healthcare industry, and the availability of new anti-fungal medications in the region, North America currently holds the largest market share for antifungal drugs and is predicted to maintain this position throughout the forecast period. Due to the rising prevalence of mucormycotic, a chronic illness-related fungal infection, Asia-Pacific is anticipated to see the highest CAGR throughout the projection of the market for antifungal medications.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
Some of the major key players are as follows: Abbott, bioMérieux SA, Cardinal Health, Inc., F. Hoffmann-La Roche Ltd, BD, General Electric Company, Hologic, Inc, Siemens Medical Solutions USA, Inc., Quest Diagnostics Incorporated, Koninklijke Philips N.V. and Others Players.
General Electric Company-Company Financial Analysis
|Market Size in 2022
|US$ 15.21 Billion
|Market Size by 2020
|US$ 20.03 Billion
|CAGR of 3.5% From 2023 to 2030
|Report Scope & Coverage
|Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
|• By Drug Class (Azoles, Polyenes, Allylamines, Echinocandins)
• By Infection Type (Superficial Antifungal Infections, Systemic Antifungal Infections)
• By Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others)
• By Dosage Forms (Oral, Topical, Others)
|North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Abbott, bioMérieux SA, Cardinal Health, Inc., F. Hoffmann-La Roche Ltd, BD, General Electric Company, Hologic, Inc, Siemens Medical Solutions USA, Inc., Quest Diagnostics Incorporated, Koninklijke Philips N.V.
|• Awareness of the Many Fungal Infections is Growing
• More and more over-the-counter antifungal medications (OTC)
|• Issues with Medicine
• Drug Resistance to Antifungals is Growing
Ans. Anti-Fungal Treatment Market Size was valued at USD 15.21 billion in 2022.
Ans: The Anti-Fungal Treatment Market is growing at a CAGR of 3.5% over the forecast period 2023-2030.
Ans. North America currently holds the largest market share for antifungal market.
Ans. Manufacturer and service provider, research institutes, university and private libraries, suppliers and distributers
Ans. Anti-Fungal Treatment market is divided in four segments and they are By Drug Class, By Infection Type, By Therapeutic Indications, and By Dosage Forms
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
220.127.116.11 United Kingdom
18.104.22.168 South Korea
22.214.171.124 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Anti-Fungal Treatment Market Segmentation, By Drug Class
9. Anti-Fungal Treatment Market Segmentation, By Infection Type
9.1 Superficial Antifungal Infections
9.2 Systemic Antifungal Infections
10. Anti-Fungal Treatment Market Segmentation, By Therapeutic Indications
11. Anti-Fungal Treatment Market Segmentation, By Dosage Forms
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13. Company Profiles
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 bioMérieux SA
13.3 Cardinal Health, Inc.
13.4 F. Hoffmann-La Roche Ltd
13.6 General Electric Company
13.7 Hologic, Inc
13.8 Siemens Medical Solutions USA, Inc.
13.9 Quest Diagnostics Incorporated
13.10 Koninklijke Philips N.V.
14. Competitive Landscape
14.1 Competitive Benchmark
14.2 Market Share Analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Medical Device Connectivity Market Size was valued at USD 2.24 billion in 2022, and is expected to reach USD 12.93 billion by 2030 and grow at a CAGR of 24.5% over the forecast period 2023-2030.
The Healthcare Supply Chain Management Market is expected to reach USD 4.67 billion by 2030, and Size was valued at USD 2.52 billion in 2022, and grow at a CAGR of 8.0 % over the forecast period 2023-2030.
The Healthcare Cold Chain Monitoring Market Size was valued at USD 3.40 billion in 2022, and is expected to reach USD 8.74 billion by 2030, and grow at a CAGR of 12.5% over the forecast period 2023-2030.
The PET-CT Scanner Device Market size was estimated USD 2.3 billion in 2022 and is expected to reach USD 4.0 billion by 2030 at a CAGR of 7.2% during the forecast period of 2023-2030.
The Antibiotics Market size is valued at USD 49.51 Bn in 2022 and is expected to reach USD 68.22 Bn by 2030 and grow at a CAGR of 4.09% over the forecast period of 2023-2030.
The Blood Group Typing Market was estimated at USD 1.98 billion in 2022 and is poised to reach at 4.18 billion in 2030 anticipated to expand at a compound annual growth rate approx. CAGR of 9.8% for the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone